


**AMENDMENTS TO THE CLAIMS:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-7. Canceled.

8. (Currently Amended) A 2-aminoteraline of the formula (I)



or a pharmacologically acceptable salt of the formula (II)



wherein:

R and R<sub>1</sub> are independently halogen, hydroxy, or C<sub>1</sub>-C<sub>4</sub> alkoxy optionally substituted in position ω with a group selected from OH, NH<sub>2</sub> or NR<sub>3</sub>R<sub>4</sub>, wherein R<sub>3</sub> and R<sub>4</sub> are independently H, C<sub>1</sub>-C<sub>4</sub> alkyl, unsubstituted or substituted in position ω with groups OH, NH<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> alkanoyl, C<sub>1</sub>-C<sub>4</sub> alkyl, carbamoyl, carbamoyloxy, amino, or amino-substituted NR<sub>3</sub>R<sub>4</sub>, where R<sub>3</sub> and R<sub>4</sub> have the above meanings,

R<sub>2</sub> is hydrogen, hydroxy or methoxy,

with the proviso that the 2-aminotetraline excludes (a) R=R<sub>1</sub>=CH<sub>3</sub>O or OH, R<sub>2</sub>=H, (b) R=F, R<sub>1</sub>=CH<sub>3</sub>O or OH, R<sub>2</sub>=H, (c) R<sub>1</sub>=R<sub>2</sub>=-OCH<sub>3</sub> and R<sub>2</sub>=H, (d) R=R<sub>1</sub>=R<sub>2</sub>=CH<sub>3</sub>O, (e) R=R<sub>1</sub>=Cl and R<sub>2</sub>=H, (f) R=R<sub>1</sub>-F and R<sub>2</sub>=H, (g) R=OH and R<sub>1</sub>=R<sub>2</sub>=halogen, (h) R=R<sub>1</sub>=OH and R<sub>2</sub>=Cl or F or (i) R=R<sub>1</sub>=OCH<sub>3</sub> and R<sub>2</sub>=Cl or F, (j) R=Cl, R<sub>1</sub>=OH, R<sub>2</sub>=H, (k) R=MeOH, R<sub>1</sub>=Cl, R<sub>2</sub>=H, (l) R=Cl, R<sub>1</sub>=MeOH, R<sub>2</sub>=H

and X<sup>-</sup> is the monovalent anion of a pharmacologically acceptable acid.

9. (Previously Presented) A compound according to claim 8, wherein the monovalent anion of a pharmacologically acceptable acid is selected from chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.

10. (Currently Amended) A compound selected from the group consisting of:

~~S(-)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;~~

~~R(+)-2-amino-6-fluoro-7-hydroxytetraline hydrochloride;~~

(R,S)-2-amino-5,6-difluoro-7-methoxytetraline hydrochloride;

(R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride;

(R,S)-2-amino-7-fluoro-6-hydroxytetraline hydrochloride;

(R,S)-7-acetyl-2-amino-6-methyltetraline hydrochloride; and

(R,S)-2-amino-7-fluoro-6-methoxytetraline hydrochloride.

11. (Previously Presented) An orally or parenterally administrable pharmaceutical composition containing a compound of claim 8 and a pharmaceutically acceptable carrier and/or diluent.

12-20. canceled.